Cargando…

P1653: CLINICAL EFFICACY AND SAFETY OF SWITCHING ELTROMBOPAG AND RH-TPO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA DURING THE COVID-19 PANDEMIC

Detalles Bibliográficos
Autores principales:	Cai, X., Zhang, X.-H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430477/ http://dx.doi.org/10.1097/01.HS9.0000849468.68112.e2

Ejemplares similares

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
por: Zhu, Qiuhua, et al.
Publicado: (2021)

Management of COVID-19-related immune thrombocytopenia by rhTPO
por: Zhang, Xuzhao, et al.
Publicado: (2021)

P1632: PROSPECTIVE OBSERVATIONAL STUDY IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) TREATED WITH TPO-R AGONISTS (TPO-RA): ELTROMBOPAG (EPAG) AND ROMIPLOSTIM (ROMI) - THE PEPITE STUDY
por: Chèze, S., et al.
Publicado: (2022)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

P1653: INFLAMMATION MEDIATED THROMBUS FORMATION IN LYMPHOMAS
por: Antic, Darko, et al.
Publicado: (2023)

P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
por: Dangudubiyyam, S., et al.
Publicado: (2022)

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
por: Cai, Xuan, et al.
Publicado: (2022)

P1641: ELTROMBOPAG TREATMENT, OUTCOMES AFTER DISCONTINUATION IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA, AND EXPLORATION OF POTENTIAL PREDICTIVE FACTORS: A REAL-WORLD CLINICAL EXPERIENCE
por: Liu, X., et al.
Publicado: (2022)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
por: Lambert, Michele P
Publicado: (2016)

Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia
por: Maraziti, Giorgio, et al.
Publicado: (2021)

P1634: EFFICACY AND SAFETY OF ELTROMBOPAG IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION PATIENTS WITH THROMBOCYTOPENIA（HBV-TP）: A PROSPECTIVE, MULTI-CENTER, SINGLE ARM, PHASE II TRAIL
por: Chen, Y., et al.
Publicado: (2022)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
por: 吴, ?.
Publicado: (2022)

P1639: UTILITY OF NEXT GENERATION SEQUENCING TECHNIQUES TO EVALUATE POSSIBLE CAUSES OF REFRACTORINESS TO TREATMENT WITH ELTROMBOPAG IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN SPAIN.
por: Gonzalez-Lopez, T. J., et al.
Publicado: (2022)

Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme
por: González-López, Tomás José, et al.
Publicado: (2023)

A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer
por: Xu, Yunhua, et al.
Publicado: (2018)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022)

Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag
por: Tarantino, Michael D., et al.
Publicado: (2014)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
por: Özdemirkıran, Füsun, et al.
Publicado: (2015)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia
por: Di Paola, Alessandra, et al.
Publicado: (2020)

Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study
por: Cheng, Xiaoling, et al.
Publicado: (2019)

Successful Use of Eltrombopag in a Young Child With Chronic Immune Thrombocytopenia
por: Gruhn, Bernd, et al.
Publicado: (2021)

Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis
por: Ahmed, Hafiz Abdul Waqas, et al.
Publicado: (2021)

Eltrombopag use for refractory immune thrombocytopenia in pregnancy: A case report
por: Weingarten, Sarah J., et al.
Publicado: (2020)

Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis
por: Patwardhan, Pallavi, et al.
Publicado: (2021)

Eltrombopag in long‐term management of pediatric thrombocytopenia
por: Shah, Sanjay J., et al.
Publicado: (2018)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia
por: Matsumoto, Megumi, et al.
Publicado: (2022)

Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia
por: Park, Rojin
Publicado: (2015)

A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag
por: Yoon, Jung-Ki, et al.
Publicado: (2019)

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey
por: Koca Yozgat, Ayça, et al.
Publicado: (2020)

A case of immune thrombocytopenia due to miliary tuberculosis effectively treated with eltrombopag
por: Wada, Hiroshi, et al.
Publicado: (2020)

Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia
por: Nomura, Shosaku, et al.
Publicado: (2021)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
por: Kaur, Manraj N., et al.
Publicado: (2022)

Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells
por: Di Paola, Alessandra, et al.
Publicado: (2021)

Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study
por: Hong, Yilei, et al.
Publicado: (2023)

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
por: Profit, Louise
Publicado: (2006)

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome
por: Xu, Liping, et al.
Publicado: (2022)

P1654: COMPLEMENT ACTIVATION REGULATES PLATELET HOMEOSTASIS BY ARRESTING THE ANTI-INFLAMMATORY EFFECTS OF INTERLEUKIN-35 IN IMMUNE THROMBOCYTOPENIA
por: Gui, R.-Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_okg8psab6b0djbnhsj16n8iao6